全文获取类型
收费全文 | 50884篇 |
免费 | 4540篇 |
国内免费 | 894篇 |
专业分类
耳鼻咽喉 | 251篇 |
儿科学 | 2361篇 |
妇产科学 | 819篇 |
基础医学 | 5086篇 |
口腔科学 | 995篇 |
临床医学 | 6686篇 |
内科学 | 7891篇 |
皮肤病学 | 690篇 |
神经病学 | 809篇 |
特种医学 | 815篇 |
外国民族医学 | 1篇 |
外科学 | 5960篇 |
综合类 | 7296篇 |
现状与发展 | 7篇 |
预防医学 | 10041篇 |
眼科学 | 292篇 |
药学 | 4163篇 |
41篇 | |
中国医学 | 1017篇 |
肿瘤学 | 1097篇 |
出版年
2024年 | 146篇 |
2023年 | 937篇 |
2022年 | 1862篇 |
2021年 | 2432篇 |
2020年 | 2478篇 |
2019年 | 1948篇 |
2018年 | 1889篇 |
2017年 | 1851篇 |
2016年 | 2007篇 |
2015年 | 2150篇 |
2014年 | 3509篇 |
2013年 | 3989篇 |
2012年 | 3478篇 |
2011年 | 3555篇 |
2010年 | 2523篇 |
2009年 | 2335篇 |
2008年 | 2202篇 |
2007年 | 2261篇 |
2006年 | 2162篇 |
2005年 | 1890篇 |
2004年 | 1556篇 |
2003年 | 1338篇 |
2002年 | 966篇 |
2001年 | 877篇 |
2000年 | 718篇 |
1999年 | 672篇 |
1998年 | 538篇 |
1997年 | 499篇 |
1996年 | 435篇 |
1995年 | 415篇 |
1994年 | 387篇 |
1993年 | 325篇 |
1992年 | 292篇 |
1991年 | 275篇 |
1990年 | 198篇 |
1989年 | 207篇 |
1988年 | 157篇 |
1987年 | 127篇 |
1986年 | 100篇 |
1985年 | 137篇 |
1984年 | 84篇 |
1983年 | 67篇 |
1982年 | 76篇 |
1981年 | 63篇 |
1980年 | 40篇 |
1979年 | 40篇 |
1978年 | 24篇 |
1977年 | 25篇 |
1976年 | 33篇 |
1975年 | 15篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
52.
颅内肿瘤切除术后颅内感染危险因素分析 总被引:1,自引:0,他引:1
目的 探讨颅内肿瘤切除术后颅内感染的危险因素和预防措施。方法 回顾性分析442例颅内肿瘤切除术患者的临床资料。结果 442例颅内肿瘤切除术患者发生颅内感染33例,感染率为7.47%。非脑膜瘤手术颅内感染率为10.04%,高于脑膜瘤术后颅内感染率3.83%(P〈0.05);手术时间≥4h者颅内感染率为9.87%,高于手术时间〈4h者颅内感染率4.78%(P〈0.05);有脑脊液漏者颅内感染率为15.00%,高于无脑脊液漏者颅内感染率6.28%(P〈0.05);引流管留置≥24h者颅内感染率为11.58%,高于未留置或留置〈24h者颅内感染率5.03%(P〈0.05)。结论 手术时间≥4h、引流管留置时间≥24h、存在脑脊液漏是颅内肿瘤切除术后发生颅内感染的危险因素。 相似文献
53.
Nozha Brahmi Youssef Blel Nadia Kouraichi Salma Lahdhiri Hafedh Thabet Abderrazek Hedhili Mouldi Amamou 《Journal of infection and chemotherapy》2006,12(4):190-194
The present study included three periods: (1) a 12-month prerestriction and control period in 2001; (2) a 12-month restriction
period with reduced ceftazidime prescribing in favor of piperacillin-tazobactam (2002); (3) and a 24 month postrestriction
period (2003–2004). Note that, for results, P represents the difference between 2002 and 2001; P′, the difference between 2003 and 2001; and P″, the difference between 2004 and 2001. No changes in hygiene practices were observed during these three periods. The purpose
of this study was to assess the effect of reducing ceftazidime use in an intensive care unit (ICU) upon Gram-negative bacterial
resistance, particularly as regards Pseudomonas aeruginosa. During the three periods of the study, patients were similar concerning age, Simplified Acute Physiology Score (SAPSII),
the site of nosocomial infection, and the requirements for mechanical ventilation (75% in 2001, 76% in 2002, 74% in 2003,
and 85% in 2004). The most commonly isolated pathogens were P. aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae. The use of ceftazidime decreased significantly from 12.6% in 2001 to 9% in 2002, to 3% in 2003 (P′ = 0.0009), and 2.6% in 2004 (P″ = 0.0001) in favor of piperacillin-tazobactam (0% 2001 to 3.7% in 2003; P′ = 0.002; and 5% in 2004; P″ = 0.0001). Simultaneously, we observed a significant decrease in isolates of P. aeruginosa resistant to piperacillin-tazobactam (P = 0.03; P′ = 0.004; P″ = 0.009), and those resistant to imipenem in 2003 (P′ = 0.008). We also noted a significant decrease in A. baumannii isolates resistant to ceftazidime (P′ = 0.01; P″ = 0.0004) and those resistant to imipenem in both 2002 and 2004 (P = 0.03; P″ = 0.04), and a considerable decrease in isolates of Klebsiella pneumoniae producing expanded spectrum betalactamase (ESBL) in 2003 and 2004 (P′ = 0.04; P″ = 6.10−5). In contrast, we noted an increase in penicillinase-producing isolates of K. pneumoniae, from 6% in 2001 to 16% in 2002 (p = 0.01), 20% in 2003 (P′ = 0.001), and 32% in 2004 (P″ = 10−6). We concluded that restriction of ceftazidime use was demonstrated to be efficient in reducing antimicrobial resistance,
especially to K. pneumoniae ESBL. 相似文献
54.
55.
Mariela Dutra Gontijo Moura Soraya de Mattos Camargo Grossmann Linaena Méricy da Silva Fonseca Maria Inês Barreiros Senna Ricardo Alves Mesquita 《Journal of oral pathology & medicine》2006,35(6):321-326
BACKGROUND: Oral hairy leukoplakia (OHL) may be an indicator of the progression of Human Immunodeficiency Virus (HIV)-induced immuno-depression, and the evaluation of risk factors leading to OHL is important in the management of these HIV-infected patients. However, there are few studies that analyze risk factors leading to OHL in the Brazilian population. The aim of this case-control study is to present data about prevalence rates and risk factors leading to OHL in a sample of HIV-infected adults in Brazil. METHODS: This case-control study included 111 HIV-infected patients treated at a clinic for sexually transmitted diseases and HIV. In the initial examinations with dentists, variables were collected from all patients. Diagnosis of OHL was performed in accordance with the International Classification System and cytological features. The Fisher and the chi-squared tests were used for statistical analysis. The proportional prevalence and odds ratio were estimated. RESULTS: Outcome presented a positive, statistically significant association among the presence of OHL and viral load of 3000 copies/mul or greater (P = 0.0001; odds ratio (OR) = 5.8), presence of oral candidiasis (P = 0.0000; OR = 11.1), previous use of fluconazole (P = 0.0000; OR = 24.6), and use of systemic acyclovir (P = 0.032; OR = 4.3). Antiretroviral medication presented a negative, statistically significant association with the presence of OHL (P = 0.002; OR = 8.4). CONCLUSIONS: Prevalence of OHL was 28.8%. Viral load, oral candidiasis, previous use of fluconazole, and systemic acyclovir were determined to be risk factors for OHL. Antiretroviral medication proved to be protective against the development of OHL. 相似文献
56.
Eimear Kieran 《Current Obstetrics & Gynaecology》2006,16(4):218-225
57.
58.
Sachiko Goto Akiyoshi Tsuji Teiko Murai Minoru Nishida Hiroko Tsukano Haruo Watanabe 《Journal of infection and chemotherapy》1998,4(1):16-19
Although there are effective antibacterial agents against plague, newer antibacterial agents have been developed which show
more potent activity against other bacterial organisms, but have not been tested againstYersinia pestis. A strain ofYersinia pestis was selected (no. 22; National Institute of Infectious Diseases, Tokyo, Japan) that caused a systemic infection in mice.Y. pestis no. 22 was intraperitoneally inoculated into DDY-strain mice, and 13 oral or 6 injectable antibacterial drugs given to the
infected mice at varying doses 1 and 24 hours after infection. Levofloxacin, sparfloxacin and ofloxacin were the most effective
oral agents against the infection, and prulifloxacin and pazufloxacin were also effective but to a lesser extent. Also, gentamicin
and arbekacin were the most potent injectable antibacterial agents againstY. pestis. These results suggest that there are several new drugs, both oral and injectable, which exert excellent in vivo antibacterial
activity against a mouse infection model and may be useful for the clinical treatment of plague. 相似文献
59.
目的 探讨难治性支气管—肺部感染(难治组)衣原体、支原体两种病原体的表达。方法 应用ELISA法检测了29例难治性支气管—肺部感染两种非典型病原体急性感染指标,衣原体抗体IgM、支原体抗体IgM及冷凝集实验,并常规细菌学检查,与同期住院的普通性下呼吸道感染(普通组)40例,门诊及住院的急性上呼吸道感染(上感组)30例进行比较。结果 难治组衣原体急性感染率68.9%,显著高于普通组、上感组,上感组最低;支原体急性感染率难治组34、5%,显著高于普通组、上感组;衣原体混合支原体、衣原体混合其他致病菌感染均显著高于普通组和上感组。结论 难治性下呼吸道感染中衣原体、支原体感染率较高,且易与多种病原体混合感染,衣原体的慢性感染可能是难治感染的重要原因。 相似文献
60.
Hitoshi Tajiri M.D Kosuke Kozaiwa M.D Tokuzo Harada M.D Yoshikazu Ozaki M.D Kazunori Miki M.D Kazuo Shimizu M.D Shintaro Okada M.D. 《Pediatrics international》1991,33(3):323-326
We assessed the efficacy of a government-sponsored mass protection program in Osaka, Japan, for perinatal HBV infection in infants born to HBeAg positive HBV carrier mothers. We also evaluated the impact of optional follow-up procedures in such infants, including an evaluation of anti-HBs response and a booster dose of HBV vaccine for poor responders. The results demonstrated that this mass protection program protected 94.4% of the infants from perinatal HBV infection in the Osaka area. However, the proportion of infants with an unprotective level of anti-HBs was higher in the standard group than in the follow-up group both at 1.0 and 1.5 years of age, which was also the case for HBV events. Furthermore, the present study showed that a booster dose of vaccine in poor responders was very effective in promoting an anti-HBs response. In conclusion, we recommend that a follow-up blood test to confirm a response of anti-HBs to HBV vaccine should be performed at 4–8 weeks after the third injection of HBV vaccine in infants born to HBeAg positive HBV carrier mothers. We also recommend that a booster injection of HBV vaccine should be immediately given to poor responding infants who otherwise are at a considerable risk of developing HBV infection in late infancy. 相似文献